梅斯医学MedSci APP
医路相伴,成就大医

医学计算

医学量表、计算器 / 肿瘤 / 白蛋白-胆红素评分(ALBI)、血小板-白蛋白-胆红素评分(PAIBI)

白蛋白-胆红素评分(ALBI)、血小板-白蛋白-胆红素评分(PAIBI)

1.白蛋白水平g/L
2.总胆红素(TBIL) (μmol/L)
3.血小板计数(PLT) (x109/L)
ALBI评分:
ALBI分级:
mALBI分级:
PAIBI得分:
PAIBI分级:
ALBI-PLT得分:
ALBI-PLT分级:
血小板/白蛋白比值(PAR):
注:
ALBI评分和PAIBI得分广泛应用于肝癌,非小细胞肺癌等预后评估中,也用于肝衰等终末性肝病的预后评估中,具有较广泛的指导意义,在临床上可以结合临床指标进行综合判断。
如果再增加年龄,性别就是慢性肝病患者肝癌风险预测模型(aMAP评分),在慢性肝炎和肝癌中应用广泛。
ALBI-PLT得分与PAIBI得分的计算方法不同,因此,可能存在分级,其临床意义价值也不一样。有研究显示,ALBI-PLT得分对肝癌风险预测有一定的价值。
mALBI分级与ALBI分级相似的,仅仅将2级进一步细分为2a和2b级。如果将2a和2b合并起来,即为ALBI的2级。
链接:
ALBI分级评估肝功能(HCC)
终末期肝病MELD评分(透析人群)
慢性肝病患者肝纤维化FIB-4指数
终末期肝病预后模型(MELD评分)
慢性肝病患者肝癌风险预测模型(aMAP评分)
参考文献:
Roayaie S, Jibara G, Berhane S, et al. PALBI-An Objective Score Based on Platelets, Albumin & Bilirubin Stratifies HCC Patients Undergoing Resection & Ablation Better than Child's Classification. The Liver Meeting. San Francisco, USA: American Association for the Study of Liver Diseases 2015.

Hu K, Yuan J, Tang B, Zhang F, Lu S, Chen R, Zhang L, Ren Z, Yin X.Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment.Ann Transl Med. 2021 Feb;9(3):237. doi: 10.21037/atm-20-3118

Pang Q, Liu S, Wang L, Pan H, Wang C, Zhou L, Lu Y, Liu H.The Significance of Platelet-Albumin-Bilirubin (PALBI) Grade in Hepatocellular Carcinoma Patients Stratified According to Platelet Count.Cancer Manag Res. 2020 Dec 14;12:12811-12822. doi: 10.2147/CMAR.S277013

Chen PH, Hsieh WY, Su CW, Hou MC, Wang YP, Hsin IF, Yang TC, Liao WC, Lin HC, Lee FY, Wu JC. Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices,Gastrointest Endosc. 2018 Aug;88(2):230-239.e2

Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: A multicenter analysis. Liver Cancer. 2019;8(2):121–129. doi: 10.1159/000488778

评论区 (0)
#插入话题
下载本评分表二维码
* 评分系统由梅斯医学-->医学量表、计算器提供支持



移动应用
medsci.cn © 2020